Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
54
NKTR Quote, Financials, Valuation and Earnings
Last price:
$26.70
Seasonality move
:
3.02%
Day range:
$23.45 - $26.89
52-week range:
$6.48 - $37.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.27x
P/B ratio:
24.09x
Volume:
1.3M
Avg. volume:
3.5M
1-year change:
22.62%
Market cap:
$330.9M
Revenue:
$98.4M
EPS (TTM):
-$9.60
Earnings Data
Next earnings date for NKTR
Aug 08
2025
Most recent earnings per share
-$3.60
Missed by $0.78
(May 8/2025)
Consensus Estimate
-$2.82
(May 8/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
NKTR Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 09/30/2025 | Q3 | $9.5M | -- | -- | -$2.62 | -- |
| 08/08/2025 | Q2 | $9.4M | -- | -- | -$3.12 | -- |
| 05/08/2025 | Q1 | $15.4M | $10.5M | -$3.60 | -$2.82 | -$0.78 |
| 03/12/2025 | Q4 | $36.7M | $29.2M | $0.45 | -$2.93 | $3.38 |
| 11/07/2024 | Q3 | $18.3M | $24.1M | -$2.70 | -$3.09 | $0.39 |
| 08/08/2024 | Q2 | $17.5M | $23.5M | -$3.75 | -$3.01 | -$0.74 |
| 05/09/2024 | Q1 | $15.3M | $21.6M | -$2.85 | -$3.08 | $0.23 |
| 03/04/2024 | Q4 | $21.4M | $23.9M | -$3.30 | -$2.94 | -$0.36 |
| 11/07/2023 | Q3 | $21.3M | $24.1M | -$3.60 | -$2.40 | -$1.20 |
| 08/08/2023 | Q2 | $21.8M | $20.5M | -$4.05 | -$3.30 | -$0.75 |
| 05/09/2023 | Q1 | -- | $21.6M | -$10.95 | -- | -- |
| 02/28/2023 | Q4 | -- | $22M | -$4.80 | -- | -- |
| 11/03/2022 | Q3 | -- | $23.6M | -$4.65 | -- | -- |
| 08/04/2022 | Q2 | -- | $21.6M | -$12.75 | -- | -- |
| 05/05/2022 | Q1 | -- | $24.8M | -$7.35 | -- | -- |
| 02/28/2022 | Q4 | -- | $25M | -$11.85 | -- | -- |
| 11/04/2021 | Q3 | -- | $24.9M | -$10.50 | -- | -- |
| 08/05/2021 | Q2 | -- | $28.3M | -$10.35 | -- | -- |
| 05/06/2021 | Q1 | -- | $23.6M | -$10.20 | -- | -- |
| 02/25/2021 | Q4 | -- | $23.5M | -$9.75 | -- | -- |
| 11/05/2020 | Q3 | -- | $30M | -$9.15 | -- | -- |
| 08/06/2020 | Q2 | -- | $48.8M | -$6.75 | -- | -- |
| 05/07/2020 | Q1 | -- | $50.6M | -$11.70 | -- | -- |
| 02/27/2020 | Q4 | -- | $33.9M | -$9.60 | -- | -- |
| 11/06/2019 | Q3 | -- | $29.2M | -$8.40 | -- | -- |
| 08/08/2019 | Q2 | -- | $23.3M | -$9.45 | -- | -- |
| 05/08/2019 | Q1 | -- | $28.2M | -$10.35 | -- | -- |
| 02/28/2019 | Q4 | -- | $39.8M | -$8.55 | -- | -- |
| 11/07/2018 | Q3 | -- | $27.8M | -$8.40 | -- | -- |
| 08/08/2018 | Q2 | -- | $1.1B | $79.95 | -- | -- |
| 05/10/2018 | Q1 | -- | $38M | -$9.00 | -- | -- |
| 03/01/2018 | Q4 | -- | $95.5M | -$3.15 | -- | -- |
| 11/07/2017 | Q3 | -- | $152.9M | $5.55 | -- | -- |
| 08/08/2017 | Q2 | -- | $34.6M | -$5.85 | -- | -- |
| 05/09/2017 | Q1 | -- | $24.7M | -$6.30 | -- | -- |
| 03/01/2017 | Q4 | -- | $37.5M | -$4.20 | -- | -- |
| 11/03/2016 | Q3 | -- | $36.3M | -$4.80 | -- | -- |
| 08/03/2016 | Q2 | -- | $32.8M | -$5.40 | -- | -- |
| 05/03/2016 | Q1 | -- | $58.9M | -$2.10 | -- | -- |
| 03/01/2016 | Q4 | -- | $39.4M | -$6.00 | -- | -- |
| 11/05/2015 | Q3 | -- | $60M | -$0.90 | -- | -- |
Nektar Therapeutics Earnings Questions
-
How Much did Nektar Therapeutics Generate in Revenue Last Quarter?
Nektar Therapeutics reported $10.5M worth of top line sales in its most recent quarter.
-
Did Nektar Therapeutics Beat Earnings Last Quarter?
Nektar Therapeutics announced earnings per share of -$3.60 which represents a miss of analyst forecast a -$2.82 per share.
-
Is Nektar Therapeutics Profitable?
Nektar Therapeutics reported $10.5M that represents $0.74 per share over the last quarter.
-
What is the Analyst Consensus for Nektar Therapeutics EPS Next Year?
Nektar Therapeutics's earnings are forecast to decrease from -$8.70 per share to -$12.00 per share next year representing a decrease of -28.58%.
-
When is Nektar Therapeutics's Earnings Date?
Nektar Therapeutics's next earnings date is August 8, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
